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Phenotypic heterogeneity in IGHV-mutated CLL patients has
prognostic impact and identiﬁes a subset with increased
sensitivity to BTK and PI3Kδ inhibition
Leukemia (2015) 29, 744–747; doi:10.1038/leu.2014.308
The majority of chronic lymphocytic leukemia (CLL) patients are
diagnosed with early-stage disease but the currently used
prognostic tools appear to be less informative in this group of
patients.1 This is especially problematic for patients with mutated
immunoglobulin genes (M-CLL) as they have a more diverse
clinical course when compared with patients with unmutated
immunoglobulin genes (U-CLL).1–4 Given the emergence of
promising targeted, less toxic, therapeutics in CLL,5,6 there is an
increased need to identify patients who might beneﬁt from early
treatment with these new agents.
Chemokine receptors expressed on CLL cells are thought to
regulate the trafﬁcking of the leukemic cells between blood and
lymphoid tissues.5 Logically, the tendency of CLL cells to return to
tissue sites where they are cytoprotected and are driven to
proliferate contributes to clinical aggressiveness. It is therefore
possible that these receptors represent promising prognostic
markers and potentially useful therapeutic targets. We previously
reported that one such chemokine receptor, CXCR4, is associated
with poor clinical outcome in an unselected cohort of CLL
patients.7 Here we speciﬁcally focused our attention on M-CLL
samples to ascertain the impact of CXCR4 expression in this
clinically heterogeneous subset. The cohort was made up of 60
M-CLL patients from the original study and 64 additional M-CLL
patients. The patient characteristics are given in Supplementary
Table 1. CXCR4 expression was determined using the three-color
ﬂow cytometric assay described previously.7 We used the median
expression as a binary classiﬁer based on receiver operating
characteristic analysis. Of the 124 M-CLL samples analyzed, 50
(40.4%) were classiﬁed as CXCR4hi and 74 (59.6%) as CXCR4lo;
M-CLL patients showed much more heterogeneity in CXCR4
expression than U-CLL (Figure 1a). Importantly, elevated CXCR4
expression in M-CLL was a strong determinant of reduced overall
survival (Figure 1b; hazard ratio (HR) = 3.5). As M-CLL patients
utilizing IGHV3-21 genes have been shown to have an inferior
clinical outcome,8,9 we asked whether the CXCR4 expression was
signiﬁcantly different in the IGHV3-21 subset. We found no
signiﬁcant increase in CXCR4 expression in IGHV3-21 samples
when compared with samples utilizing other IGHV gene segments
(Supplementary Figure 1; P= 0.92). Similarly, we found no
association between CXCR4 expression and the high-risk cytoge-
netic risk groups (Supplementary Figure 1; P= 0.41).
We recently showed a strong association between CXCR4
expression and CD49d in an unselected cohort of U-CLL and
M-CLL patients.7 We therefore examined the expression of
CD49d in this M-CLL subset using the same ﬂow cytometric
methodology and determined its prognostic relevance. In
concordance with our CXCR4 data, there was heterogeneous
expression of CD49d with 60 (47.4%) CD49dhi and 64(52.6%)
CD49dlo. Again this heterogeneity was in marked contrast to
U-CLL cases (Figure 1c). Furthermore, CD49dhi patients (430%
positive) had a signiﬁcantly worse clinical outcome than CD49dlo
patients (Figure 1d; HR = 3.4) reinforcing the credentials of
CD49d as a prognostic marker in the M-CLL subset.10 When
assessed as continuous variables, CXCR4 and CD49d were
strongly correlated (Figure 1e; Po0.0001). Using categorical
cutoffs to deﬁne the cohort, the majority of M-CLL cases showed
concordant expression for CXCR4 and CD49d: CXCR4hi/CD49dhi
or CXCR4lo/CD49dlo. However, 27% of the subset was discordant
for these markers (Supplementary Figure 2). The Kaplan–Meier
curve for the discordant cases bisected the CXCR4hi/CD49dhi and
CXCR4lo/CD49dlo curves highlighting the prognostic importance
of both CXCR4 and CD49d and suggesting that the combined
assessment of CXCR4 and CD49d has clinical utility. This was
supported by the observation that the combination of CXCR4
and CD49d was a more powerful prognostic tool than either
marker alone for the concordant cases (Figure 1f; HR = 5.2).
It is worthy of note that CXCR4hi/CD49dhi M-CLL cases had a
similar clinical outcome when compared with U-CLL cases
(Supplementary Figure 3).
We went on to establish the functional signiﬁcance of CXCR4
and CD49d expression in M-CLL. CXCR4hi/CD49dhi samples
showed signiﬁcantly increased migration in response to CXCL12
in transwell experiments (Figure 2a; P= 0.012), which could be
inhibited by both plerixafor (CXCR4 antagonist) and natalizumab
(anti-CD49d antibody) even in the presence of CXCL12 (Figure 2b).
We observed a signiﬁcant reduction in CXCR4 expression when
CLL cells were incubated with CXCL12 presumably owing to the
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internalization of the receptor (Supplementary Figure 4a). No
change in CD49d expression was seen under these conditions
(Supplementary Figure 4b). There is now a growing appreciation
that the propensity of CLL cells to home to lymphoid tissues
contributes to the clinical course of CLL.11,12 We recently showed
that CXCR4hi and CD49dhi samples have a higher propensity to
undergo transendothelial migration in a dynamic in vitro model of
the peripheral vasculature of CLL suggesting that these molecules
contribute to this process.12 The importance of CLL cell migration
is perhaps best exempliﬁed by the remarkable clinical effect of the
BTK and PI3Kδ inhibitors ibrutinib and idelalisib.13 Both drugs
promote a redistribution of CLL cells into the peripheral
vasculature from lymphoid tissues characterized by a rapid
increase in peripheral lymphocytosis. These cells appear then to
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Figure 1. Differential expression and prognostic impact of CXCR4 and CD49d in M-CLL. (a) We analyzed the expression of CXCR4 in a cohort of
124 serially collected M-CLL samples and used the median expression as a binary classiﬁer based on receiver operating characteristic analysis.
M-CLL patients showed a much more heterogeneous expression of CXCR4 than U-CLL cases. (b) M-CLL patients with a CXCR4hi phenotype
had a signiﬁcantly inferior outcome when compared with CXCR4lo patients. (c) The cohort was then categorized into CD49dlo (o30%
expression) and CD49dhi (⩾30% expression) subsets. Again M-CLL cases showed much more heterogeneity in the expression of CD49d than
U-CLL cases. (d) M-CLL patients with a CD49dhi phenotype had a signiﬁcantly inferior outcome when compared with CD49dlo patients.
(e) When assessed as continuous variables, CXCR4 and CD49d were strongly correlated. Similarly, using categorical cutoffs to deﬁne the cohort, the
majority of M-CLL cases showed concordant expression for CXCR4 and CD49d: CXCR4hi/CD49dhi or CXCR4lo/CD49dlo. 27% of the cases were
discordant for these markers. (f ) The Kaplan–Meier curves for the discordant cases bisected the CXCR4hi/CD49dhi and CXCR4lo/CD49dlo curves
highlighting the prognostic importance of both CXCR4 and CD49d and suggesting that the combined assessment of CXCR4 and CD49d has
clinical utility.
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Figure 2. CXCR4hi/CD49dhi M-CLL cases are functionally distinct from CXCR4lo/CD49dlo M-CLL cases. In vitro migration assays were performed
using 3.0-μm pore size transwell migration plates (Costar, Corning, NY, USA). A total of 106 CLL cells in 500 μl of RPMI containing 10% fetal calf
serum (FCS) were added to the upper chamber of the transwell insert. 100 ng/ml of CXCL12 was added to the lower wells. The plates were
incubated for 4 h at 37 °C in 5% CO2. Controls without CXCL12 were maintained in each experiment to account for passive diffusion of cells
(o1.5% in every case). (a) CXCR4hi/CD49dhi samples (n= 10) showed signiﬁcantly increased migration in response to CXCL12 when compared
with CXCR4lo/CD49dlo samples (n= 10). (b) Addition of plerixafor (100 μM) or natalizumab (1 μg/ml) to the upper chamber of the transwell
insert signiﬁcantly inhibited CLL cell migration despite the presence of a CXCL12 chemokine gradient (n= 8). Exposure to ibrutinib or idelalisib
for 24 h resulted in a signiﬁcant reduction in (c) CXCR4 expression and (d) Cd49d expression in the viable CD19+/CD19+ CLL cells. (e) Although
CXCR4 hi/CD49dhi samples were inherently more migratory than CXCR4lo/CD49dlo samples, incubation with ibrutinib (10 μM) and idelalisib
(10 μM) for 4 h induced a signiﬁcantly larger percentage reduction in migration in CXCR4hi/CD49dhi samples. (f) CLL cells derived from M-CLL
patients were maintained in vitro in RPMI supplemented with 10% FCS and 5 ng/ml interleukin-4 in the presence or absence of 10 μM ibrutinib.
After 48 h apoptosis was assessed using Annexin V and propidium iodide labeling. CXCR4hi/CD49dhi samples (n= 9) showed signiﬁcantly
increased apoptotic cell death in response to ibrutinib and idelalsib when compared with CXCR4lo/CD49dlo samples (n= 10). All paired and
unpaired observations were analyzed using the Student’s t-test after conﬁrming that the data were Gaussian or a Gaussian approximation
using the omnibus K2 test.
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be trapped in the peripheral vasculature where, in the absence of
prosurvival and proproliferative signals, they are potentially more
susceptible to spontaneous apoptosis and chemotherapeutic
agents. Although these drugs are currently being trialed in
patients with progressive or advanced stage disease,14,15 their
side-effect proﬁles are modest and so it seems likely that they will
be considered as frontline treatment options in early-stage
asymptomatic patients. This being the case, it will be crucial to
accurately identify those patients who might beneﬁt from early
treatment and equally those who may not require treatment at all.
Intriguingly, a recent study indicated that M-CLL patients had an
inferior response to ibrutinib when compared with U-CLL
patients.6 Here we show that both drugs caused a signiﬁcant
reduction in CXCR4 expression (Figure 2c) and CD49d expression
(Figure 2d). Furthermore, despite the enhanced migratory proper-
ties of CXCR4hi/CD49dhi M-CLL samples ibrutinib and idelalisib
induced a signiﬁcantly greater percentage reduction in the
migration of CXCR4hi/CD49dhi M-CLL samples (mean migration
9.44 ± 2.08% to 4.00 ± 1.12%) when compared with CXCR4lo/
CD49dlo samples (mean migration 8.75 ± 1.61% to 4.97 ± 0.85%;
Figure 2e). In addition, CXCR4hi/CD49dhi M-CLL samples were
more susceptible to the apoptotic effects of ibrutinib and idelalisib
(Figure 2f). These ﬁndings suggest that CXCR4hi/CD49dhi M-CLL
patients are more dependent on BTK and PI3Kδ signaling, and
hence could particularly beneﬁt from treatment with inhibitors of
these kinases.
Taken together, our data provide evidence that CXCR4 and
CD49d are important modulators of prognosis in M-CLL
patients. Furthermore, the combination of CXCR4 and CD49d
measurement provided even greater prognostic resolution for
concordant M-CLL cases. This knowledge could facilitate
enhanced ﬂow cytometry-based risk stratiﬁcation for this hetero-
geneous group of patients and identify those who might
particularly beneﬁt from BTK or PI3Kδ inhibitors or therapeutics
designed to target the function of CXCR4 and CD49d. Similarly, it
could delineate a substantial population of CXCR4lo/CD49dlo
M-CLL patients with very low risk of disease progression who
could be monitored less frequently.
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